- Home
- CEP vs CHRS Comparison
CEP vs CHRS Comparison
Compare CEP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEP
- CHRS
- Stock Information
- Founded
- CEP 2020
- CHRS 2010
- Country
- CEP United States
- CHRS United States
- Employees
- CEP N/A
- CHRS N/A
- Industry
- CEP
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CEP
- CHRS Health Care
- Exchange
- CEP NYSE
- CHRS Nasdaq
- Market Cap
- CEP 516.2M
- CHRS 112.5M
- IPO Year
- CEP 2024
- CHRS 2014
- Fundamental
- Price
- CEP $42.13
- CHRS $0.77
- Analyst Decision
- CEP
- CHRS Buy
- Analyst Count
- CEP 0
- CHRS 3
- Target Price
- CEP N/A
- CHRS $4.68
- AVG Volume (30 Days)
- CEP 3.4M
- CHRS 1.5M
- Earning Date
- CEP 01-01-0001
- CHRS 05-12-2025
- Dividend Yield
- CEP N/A
- CHRS N/A
- EPS Growth
- CEP N/A
- CHRS N/A
- EPS
- CEP 0.25
- CHRS N/A
- Revenue
- CEP N/A
- CHRS $272,251,000.00
- Revenue This Year
- CEP N/A
- CHRS N/A
- Revenue Next Year
- CEP N/A
- CHRS $19.78
- P/E Ratio
- CEP $159.75
- CHRS N/A
- Revenue Growth
- CEP N/A
- CHRS 19.87
- 52 Week Low
- CEP $9.99
- CHRS $0.66
- 52 Week High
- CEP $59.75
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- CEP N/A
- CHRS 39.42
- Support Level
- CEP N/A
- CHRS $0.74
- Resistance Level
- CEP N/A
- CHRS $0.82
- Average True Range (ATR)
- CEP 0.00
- CHRS 0.06
- MACD
- CEP 0.00
- CHRS -0.00
- Stochastic Oscillator
- CEP 0.00
- CHRS 23.41
About CEP CANTOR EQUITY PARTNERS INC
Cantor Equity Partners Inc is a blank check company.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.